Dossier assessment
Dupilumab (chronic rhinosinusitis with nasal polyposis) - Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Dupilumab (chronic rhinosinusitis with nasal polyposis) - Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Dupilumab (chronic rhinosinusitis with nasal polyposis) - Benefit assessment according to §35a Social Code Book V
Dossier assessment
Adults with severe chronic rhinosinusitis with nasal polyposis for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control
Proof of added benefit, extent: non-quantifiable, at least considerable
Press releases
Dupilumab for chronic rhinosinusitis with nasal polyposis: proof of added benefit
Project details
- Project no.
- A19-96
- Commission
- Commission awarded on 21.11.2019 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Airways and respiratory system
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Connected Projects
-
Dossier assessment
Dupilumab (atopic dermatitis in adolescents) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Dupilumab (asthma) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Dupilumab (atopic dermatitis) - Benefit assessment according to §35a Social Code Book (SGB) V
Status: Commission completed
-
Dossier assessment
Dupilumab (chronic spontaneous urticaria in children >= 2 to < 12 years) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Dupilumab (chronic spontaneous urticaria in adults and adolescents 12 years and above) – Benefit assessment according to §35a
Status: Commission completed
-
Dossier assessment
Dupilumab (eosinophilic oesophagitis, 1 to 11 years) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Dupilumab (atopic dermatitis in children) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Dupilumab (severe asthma with type 2 inflammation) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Dupilumab (prurigo nodularis) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Dupilumab (COPD) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Dupilumab (atopic dermatitis, 6 months to 5 years) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Dupilumab (eosinophilic oesophagitis) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed